Cariprazine in the treatment of schizophrenia: a proof-of-concept trial

This 6-week, double-blind, placebo-controlled, proof-of-concept study evaluated the efficacy, safety, and tolerability of low-dose (1.5–4.5 mg/day) and high-dose (6–12 mg/day) cariprazine in patients with acute exacerbation of schizophrenia (NCT00404573). The primary efficacy measure was change in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Durgam, Suresh, Litman, Robert E., Papadakis, Kelly, Li, Dayong, Németh, György, Laszlovszky, István
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736298/
https://www.ncbi.nlm.nih.gov/pubmed/26655732
http://dx.doi.org/10.1097/YIC.0000000000000110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736298/
https://www.ncbi.nlm.nih.gov/pubmed/26655732
http://dx.doi.org/10.1097/YIC.0000000000000110

Ejemplares similares